Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system
51 Articles
51 Articles

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system
Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology.
Data backs Medtronic MiniMed 780G for type 2, children
The MiniMed 780G automated insulin delivery system with the Simplera Sync CGM. [Image courtesy of Medtronic]Medtronic (NYSE:MDT) today shared data supporting the use of its MiniMed 780G automated insulin delivery system in a range of patients. The medtech giant highlighted improved glycemic outcomes for those with type 2 diabetes and in young children. Investigators shared data at the American Diabetes Association’s 85th Scientific Sessions in C…
Coverage Details
Bias Distribution
- 77% of the sources are Center
To view factuality data please Upgrade to Premium